The health care overhaul bill produced by House Democrats would impose an array of new taxes, fees and government mandates
on major players in the health industry, including drug companies and big medical-device makers headquartered in Indiana.
Lilly is opening the San Diego biotech center a year after launching a biotech R&D center in Indianapolis.
Long tracking the emergence of information technology firms involved in the health and life sciences sector, the state’s
IT trade group, TechPoint, is undergoing a mitosis of sorts to help fuel the trend. It has created Advancing
Life Science & Health Care Information Technology, or ALHIT, which will focus on growing this subset of the IT realm.
As it shrinks its work force, Indianapolis-based pharmaceutical firm Eli Lilly and Co. will move more than 1,000 employees to its corporate
center
by mid-2010.
South Carolina Attorney General Henry McMaster said Friday that the state has reached a $45 million settlement with drug maker
Eli Lilly and Co. over the company’s marketing of an anti-psychotic drug.
Sales of Eli Lilly and Co.’s newest drug were an afterthought during its Oct. 21 report on third-quarter earnings. The blood thinner Effient totaled up $22.6 million in sales—a mere 0.4 percent of Lilly’s total for
the quarter.
CEO John Lechleiter says Lilly’s pipeline has helped it rebound from significant patent losses three times during his 30-year
career at the company. He’s betting there will be a fourth.
Eli Lilly and Co. and General Electric Co. say they’ve made a breakthrough in cancer research that could help Lilly cut the size and cost of its clinical trials.
For the first time publicly, Eli Lilly and Co. officials admitted the obvious: Their pipeline products
aren’t likely to offset the revenue the company will lose after its two bestsellers, Zyprexa and Cymbalta, lose patent exclusivity.
Excluding special items, Eli Lilly and Co.’s earnings per share spike 22 percent on the strength of Alimta, Cymbalta and Humalog
sales. Lilly’s revenue rose 7 percent in the quarter over the same period of 2008,
to $5.56 billion.
Medco Health Solutions Inc. said Tuesday it will compare the blood thinner Plavix, the world’s second-best selling drug, with
Effient, a potential blockbuster drug sold by Indianapolis-based Eli Lilly and Co.
Eli Lilly and Co. will sell its manufacturing plant in Lafayette to a German company in its first major move toward reducing its work force by 5,500 employees and cutting its operating expenses by $1 billion.
Idaho is getting $13 million as part of a settlement reached with Indianapolis-based Eli Lilly and Co. over its marketing of
anti-psychotic drug Zyprexa.
Nearly 700 workers will be offered severance, new jobs
The health reform bill sponsored by U.S. Sen. Max Baucus, D-Mont., would help pay for expanded health insurance coverage
by levying fees of $13 billion a year on the health care industry. The fees would deliver a hefty bill to just
about all of Indiana’s major health care companies. But how they’re reacting to the fees is all over the map.
Eli Lilly and Co. has agreed to settle the State of South Carolina’s lawsuit that claimed Lilly improperly marketed the antipsychotic
drug Zyprexa, according to Bloomberg News.
Connecticut officials say Eli Lilly and Co. has agreed to a $25 million settlement with the state over claims the drug maker
marketed its anti-psychotic drug, Zyprexa, for unapproved uses and harmed patients.
A decision by a federal judge in Indianapolis to turn back a patent challenge to Eli Lilly and Co.’s Evista marks a major
victory for the company, says an analyst who closely follows the pharmaceutical industry.
A federal judge in Indianapolis turned back a patent challenge to Eli Lilly and Co.’s drug Evista, the company announced
late yesterday.
Eli Lilly and Co. has agreed to confidential terms to settle lawsuits brought by seven states alleging the company illegally
marketed bestselling antipsychotic drug Zyprexa, Bloomberg News reported today.
